

BOARD MEMBERS

*John J. Bernabei, President
Dennis Lewis, Vice President
Dave Bowyer, Secretary
James Rucker *
Jenna Misiti*
Sam Kapourales
Vicky Skaff
(*Public Member)*



www.wvbop.com

STAFF

*Michael L. Goff,
Executive Director &
CSMP Administrator*

*John P. Smolder,
CFO/COO*

*Matthew D. Morris,
General Counsel*

Office

*1207 Quarrier Street, 4th Floor
Charleston, WV 25301*

Phone

*(304) 558-0558
(304) 558-0572 (Fax)*

**MINUTES OF THE WEST VIRGINIA BOARD OF PHARMACY
APRIL 21, 2023, EMERGENCY MEETING**

On Friday, April 21, 2023, the West Virginia Board of Pharmacy (“Board”) convened at the West Virginia Board of Pharmacy office in Charleston, West Virginia, for an emergency meeting to discuss and consider the issues surrounding the compounding of semaglutide and actions taken by other states on the issue. The meeting was open to the public.

Board Members present:

John J. Bernabei, President, via video conference
Dennis Lewis, Vice President, via video conference
David Bowyer, Secretary, via video conference
Vicky Skaff, via video conference
James Rucker, via video conference
Jenna Misiti, via video conference

Board Staff present:

Michael Goff, Executive Director, and CSMP Administrator, via video conference
Matthew Morris, General Counsel
Krista Capehart, Director of Professional and Regulatory Affairs
Michael LeMasters, Chief Compliance Officer
Thomas Robinette, Inspector
Stephen Boykin, Inspector, via video conference
Earl Bennett, Inspector, via video conference
Donald Klamut, Inspector, via video conference
Alyssa Starcher, Inspector, via video conference

Public present:

None

President Bernabei called the emergency meeting to order and recognized that a quorum was present. In compliance with West Virginia Code § 6-9A 3(h), notice of the emergency meeting was posted on the West Virginia Secretary of State's website and listed the date, time, place and purpose of the meeting, and the facts and circumstances of the emergency. The meeting was opened with a prayer.

1. Board President Bernabei gave an overview of the nature of the emergency and opened the floor for discussion.
2. After discussion, Chief Compliance Officer (CCO) Michael LeMasters presented a guidance document created by Board Staff for Board review and discussion.
3. Director of Professional and Regulatory Affairs, Krista Capehart, explained the FDA approval process and how the salt form of the drug at issue is required to have its own FDA approval, which, at this time, the FDA has yet to grant.
4. President Bernabei emphasized the Board's responsibility to protect the public and suggested amendments to the guidance document that reflects that the salt form is not approved for human use and that we have been working with other states to produce the Board's guidance document.
5. Executive Director, Michael Goff, requested the Board enter Executive Session.
6. Board Vice President Lewis made a motion to enter Executive Session. The motion was seconded by Board Member Misiti and passed unanimously without discussion.
7. After exiting Executive Session, Board Vice President Lewis made a motion to adopt the guidance document, as amended, distribute the guidance document to all licensees, post the document to the Board website, and send a copy to the Boards of Medicine, Osteopathy, and Nursing. The motion was seconded by Board Member Skaff and passed unanimously without discussion.
8. Motion to adjourn was made by Board Vice President Lewis. The motion was seconded by Board member Skaff and passed unanimously.



John J. Bernabei, President
West Virginia Board of Pharmacy



David Bowyer, Secretary
West Virginia Board of Pharmacy